Ounce Sachs Inc. has completed an independent valuation of its intellectual-property portfolio, with ABM Sanaullah & Co. concluding a total fair value of US$37,663,543 as at 2 August 2026. The assessment covers the Group’s principal proprietary assets across MEDUSA, HYGIACTIVIA and POMME Kids, together with associated domain assets, technical know-how and supporting intellectual property. The valuation was commissioned to establish an independent and supportable benchmark for strategic financing, investor discussions, licensing and broader corporate-development initiatives.

The conclusion is led by MEDUSA, the Group’s surface-disinfection platform, which was independently valued at approximately US$37.06 million, representing the substantial majority of the total portfolio value. HYGIACTIVIA and POMME Kids were valued separately, reflecting their respective stages of development and commercial readiness, with additional value attributed to supporting domain assets. The concentration of value in MEDUSA reflects the maturity of the underlying platform and its assessed future income-generating potential, while the report separately recognises the earlier commercial stage of the Group’s developing consumer Houses.

The valuation was undertaken using an income-based framework with particular emphasis on the Relief-from-Royalty methodology, supported by independent market analysis, jurisdiction-specific revenue modelling, royalty-rate assessment and discount-rate analysis. Importantly, the valuation did not simply adopt management forecasts. Revenue assumptions were independently rebuilt on a bottom-up, market-by-market basis, with explicit adjustments for execution, regulatory, commercial and legal risk.

The independent process incorporated a broad evidential review spanning corporate and ownership documentation, laboratory and technical testing, regulatory materials, commercial due diligence, legal documentation and market evidence. In the case of MEDUSA, the valuation framework expressly incorporated a litigation-specific risk premium rather than excluding uncertainty from the analysis. HYGIACTIVIA and POMME Kids were similarly assessed according to their current technical, regulatory, manufacturing and commercial readiness.

For Ounce Sachs, the valuation establishes an important institutional baseline as the Group advances its private-capital strategy to support commercialisation, institutional development and the continued expansion of its intellectual-property portfolio. The independent valuation provides investors and counterparties with a documented reference point for the economic value attributed to the underlying IP, while maintaining the appropriate distinction between IP fair value and any future enterprise value, equity value, financing price or negotiated transaction value.

The Group views the conclusion as a disciplined starting point rather than an attempt to capitalise anticipated future growth in advance. The valuation remains conservative where commercial agreements, established trading history, regulatory pathways or market adoption have yet to be fully evidenced. As Ounce Sachs progresses regulatory approvals, manufacturing readiness, distribution, commercial revenues and strategic partnerships, those milestones may provide the basis for future reassessment of the portfolio’s value.